drugset / Trial / NCT05127746

Phase 1 Clinical Trial of DA-5207 in Healthy Adults

NCT05127746

Phase 1 Completed 51 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Timeline

Start
2021-11-25
Primary completion
2022-12-13
Completion
2022-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5207 Unknown Other
Subject Donepezil Small molecule 5 mg
Subject Donepezil Small molecule 10 mg

Indications

No indication recorded.